Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Consolidated revenue from operations stood at Rs. 111.05 crore
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
This is the first drug to receive a recommendation for this preventative indication in the European Union
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Subscribe To Our Newsletter & Stay Updated